688363 华熙生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.9104.2042.5348.72815.745
总资产报酬率 ROA (%)0.7413.3672.0356.91011.997
投入资产回报率 ROIC (%)0.8543.9632.4118.25914.678

边际利润分析
销售毛利率 (%)67.83770.32974.07173.32076.990
营业利润率 (%)8.5487.9324.02111.65917.869
息税前利润/营业总收入 (%)9.8257.8303.84411.04217.101
净利润/营业总收入 (%)7.8376.9343.1369.59115.118

收益指标分析
经营活动净收益/利润总额(%)112.745111.811155.07190.87591.276
价值变动净收益/利润总额(%)-8.0814.240-5.2120.3981.036
营业外收支净额/利润总额(%)-4.2320.213-1.193-0.950-0.018

偿债能力分析
流动比率 (X)2.3622.3402.0442.5582.447
速动比率 (X)1.5951.5161.1131.6291.741
资产负债率 (%)18.17618.14620.98917.55123.023
带息债务/全部投入资本 (%)2.7271.6300.2340.1733.478
股东权益/带息债务 (%)3,418.0635,796.13340,161.14255,551.4262,675.714
股东权益/负债合计 (%)448.306449.210374.818467.119331.894
利息保障倍数 (X)6.051-65.515-29.680-21.787-22.350

营运能力分析
应收账款周转天数 (天)63.07047.46833.18826.53823.920
存货周转天数 (天)322.230321.938307.927254.954230.122